Inicio>>Signaling Pathways>> Others>>3,6-Dihydroxyxanthone

3,6-Dihydroxyxanthone

Catalog No.GC66212

La 3,6-dihidroxixantona (compuesto 3) es un derivado de xantona. La 3,6-dihidroxixantona (compuesto 3) tiene actividad anticancerÍgena. La 3,6-dihidroxixantona (compuesto 3) puede usarse para la investigaciÓn del cÁncer.

Products are for research use only. Not for human use. We do not sell to patients.

3,6-Dihydroxyxanthone Chemical Structure

Cas No.: 1214-24-0

Tamaño Precio Disponibilidad Cantidad
500mg
63,00 $
Disponible
1g
94,50 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

3,6-Dihydroxyxanthone (compound 3) is a xanthone derivatives. 3,6-Dihydroxyxanthone (compound 3) has anticancer activity. 3,6-Dihydroxyxanthone (compound 3) can be used for cancer research[1].

3,6-Dihydroxyxanthone (compound 3) (3.906-1000 µg/mL; 24 hours) exhibits cytotoxic activity against WiDR and Vero cell lines with IC50 values of 785.58 and 1280.9 µM[1].

Cell Cytotoxicity Assay[1]

Cell Line: WiDR and Vero cell lines
Concentration: 3.906, 7.813, 15.625, 31.25, 62.5, 125, 250 and 500 µg/mL (WiDR cell line)7.813, 15.625, 31.25, 62.5, 125, 250, 500 and 1000 µg/mL (Vero cell line)
Incubation Time: 24 hours
Result: Inhibited cell activity and with IC50 values of 785.58 and 1,280.9 µM for WiDR and Vero cell lines.

Reseñas

Review for 3,6-Dihydroxyxanthone

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3,6-Dihydroxyxanthone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.